Lyfegen Secures CHF 5 Million in Series A Funding Round

Lyfegen, a leading provider in drug rebate management technology, has successfully closed an additional CHF 5 million in its Series A funding round. This significant investment was led by TX Ventures, a prominent European fintech investor, with participation from health-tech venture capital firm, aMoon, and other institutional investors. The funding is earmarked to accelerate Lyfegen's global expansion beyond its current markets in Europe, North America, and the Middle East. Lyfegen's platform addresses rising drug costs and the complexities of rebate agreements by automating and simplifying these processes for healthcare payers and pharmaceutical companies. Over 50 leading healthcare organizations across eight markets already rely on Lyfegen to manage over 4,000 rebate agreements, tracking substantial pharmaceutical revenues and rebates annually. With the backing of this new funding, Lyfegen aims to enhance the operational efficiency and compliance of healthcare organizations worldwide while extending its reach. According to Lyfegen's CEO, Girisha Fernando, the company's solutions unlock the potential of rebates and improve patient access to modern treatments. Jens Schleuniger from TX Ventures praised Lyfegen's innovative approach and expressed confidence in supporting its global scaling ambitions. Founded in 2018 and based in Basel, Switzerland, Lyfegen continues to maintain a sizable digital repository of drug pricing models, aiding its mission to revolutionize healthcare payment solutions.